Skip to main content
OpenTrials
Completed

NCT Number: NCT02048852

Manipulating Tobacco Constituents in Female Menthol Smokers

This study examines the potential effect of reducing nicotine content or menthol or both in women of reproductive age, a vulnerable population identified by the FDA in need of further research.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

UCONN Health Center, Farmington, Connecticut, United States

Loading trial locations.

About this study

Study is designed to address the following questions that have been outlined by the FDA as particular areas of interest:

  • What are the factors, including menthol and other flavorings that influence the appeal of tobacco products to vulnerable populations: What is the impact of these factors on cessation, switching tobacco products and multiple use?
  • What is the potential impact of modifying nicotine levels on dependence, and smoking rate and cessation, as well as patterns of switching products and use of multiple tobacco products?
  • Beyond nicotine, what other constituents enhance addictive properties?

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

are:

  • smoking at least 5 menthol cigarettes daily for the last year;
  • able to speak, read and understand English
  • female age 18 -45 years of age;
  • stable residence;
  • not intending to quit smoking within the next 6 weeks.

Exclusion criteria

are:

  • unstable psychiatric disorder (Psychiatric symptoms reported by patient or identified in medical record that cause current significant impairment in functioning or judgment such that the person's ability to come consistently for study appointments or render a decision regarding informed consent is in question.);
  • substance use which exceeds any of the following: marijuana use 3x/week, consuming 21 drinks/week or illicit drug use 1x/week;
  • history of cardiovascular disease;
  • current blood clot in arms or legs;
  • blood pressure >160/100;
  • unstable medical problems which may include but are not limited to immune system disorders, severe respiratory diseases, kidney or liver diseases, thyroid problems, substance abuse or dependence that would limit patients ability to follow experimental protocol (based on history and drug and alcohol questionaires) or other heart conditions. The study physician will determine whether a given medical condition is unstable and the appropriateness of study participation for a particular subject;
  • Serious quit attempts in the last 3 months (to ensure stability of smoking);
  • regular use (e.g., greater than weekly) of tobacco products other than cigarettes;
  • Currently using nicotine replacement or other tobacco cessation products (to minimize confounding effects of another product);
  • Pregnant or breastfeeding those planning to become pregnant,and those who are of childbearing potential and are not using an "acceptable form" of birthcontrol such as Depo-provera, Norplant, tubal ligation and barrier methods such as condoms or diaphragm.

Treatment and study plan

Reduced Nicotine Content- Non Menthol

Other

Switch from own brand of cigarette to a research cigarette with a Reduced Nicotine Content of 0.07mg nicotine yield without menthol.

Other names: SPECTRUM Research Cigarette - NRC 200

Reduced Nicotine Content- Menthol

Other

Switch from own brand of cigarette to Reduced nicotine level of each research cigarette to 0.07mg nicotine yield with Menthol

Other names: SPECTRUM Research Cigarette - RNC 201

Conventional Nicotine Content- Menthol

Other

Allow own brand of Conventional Nicotine-Menthol Cigarette

Other names: Own brand of Conventional Nicotine-Menthol Cigarette

Conventional Nicotine Content- Non Menthol

Other

Switch from own cigarette to a research cigarette which contains Conventional Nicotine yield.

Other names: SPECTRUM Research Cigarette - NRC 600

Primary outcomes

  1. The goal of the cigarette conditions is to find the impact of varying nicotine and menthol concentrations on smoking rate and abstinence.

    Time frame: 12 weeks

    Alter the nicotine and menthol concentrations of cigarettes administered to subjects as randomized.

Secondary outcomes

  1. Toxicant Exposure

    Time frame: 12 weeks

    Examine the effects of reduced nicotine and menthol removal on toxicant exposure for the outcomes-- cotinine, exhaled carbon monoxide, and urine carcinogens and other tobacco specific nitrosamines.

Other outcomes

  1. Cigarette content manipulations effect on a model mediating usage

    Time frame: 12 Weeks

    Examine cigarette content manipulation (nicotine reduction and menthol removal) as independent variables and the number of cigarettes recorded daily as dependent variable..Measures that will be tested for include subscales of the cigarette evaluations as well as craving, affect and mood, and self-confidence

  2. Effect of taster status

    Time frame: 12 Weeks

    To explore the moderating effects of supertasters with menthol assignments to predict compliance with treatment, cigarette taste and aversion. A logistic model will be used to predict post-treatment abstinence. The interaction between supertaster and menthol will test for the moderating effect.

Sponsors and collaborators

Lead sponsor

UConn Health

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Acronym: Menthol

Important dates

Study start
2014
Primary completion
2020
Study completion
2020
First posted
Jan 29, 2014
Registry last updated
Mar 19, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.